Compare VCIG & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VCIG | BCDA |
|---|---|---|
| Founded | 2013 | N/A |
| Country | Malaysia | United States |
| Employees | N/A | 17 |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5M | 12.4M |
| IPO Year | 2022 | N/A |
| Metric | VCIG | BCDA |
|---|---|---|
| Price | $9.20 | $1.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | ★ 1.0M | 56.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.81 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.20 | $1.00 |
| 52 Week High | $15.45 | $3.20 |
| Indicator | VCIG | BCDA |
|---|---|---|
| Relative Strength Index (RSI) | 96.34 | 57.42 |
| Support Level | $0.75 | $1.24 |
| Resistance Level | $15.45 | $1.33 |
| Average True Range (ATR) | 0.25 | 0.08 |
| MACD | 0.57 | 0.02 |
| Stochastic Oscillator | 82.08 | 80.43 |
VCI Global Ltd is a holding company. The principal activities of the Company and its subsidiaries are the provision of business Strategy consultancy and technology development. The firm organized its consulting services into three main segments: Business Strategy Consultancy; Technology development, solutions and consultancy; and Others. It derives the majority of its revenue from the Business Strategy Consultancy segment, which focuses on listing solutions, investor relations, and boardroom strategies consultancy.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).